The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Notice of Annual General Meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 13 May 2026 at 3.00 p.m. at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. Participation at the AGM...Intervacc announces breakthrough protection against Streptococcus suis infection in piglets
Intervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating sows and transferring maternal immunity to piglets. The...Year-end report January – December 2025
The Group in summary 01/10/25 01/10/24 Full year Full year -31/12/25 -31/12/24 2025 2024 Net sales 3 123 4 127 20 087 11 787 Operating loss -36 377 -18 505 ...Intervacc announces change of CEO
The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that he will leave his role as Chief Executive Officer and Group CEO. Simultaneously, the Board has appointed Carl-Johan Dalsgaard as the new Chief Executive Officer and Group CEO...Clinical studies with Strangvac have begun in the U.S. market
Intervacc AB (publ) announces that the company has started the first phase of clinical safety studies in horses in the United States as part of the approval process for Strangvac® in the U.S. The initial phase of the safety studies, involving vaccination of horses in...Nyhetstjänster
